Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00403520|
Recruitment Status : Completed
First Posted : November 23, 2006
Last Update Posted : July 14, 2014
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease||Drug: Experimental 1 Drug: Placebo Comparator||Phase 4|
The development of a new automated method of measurement of the volume of the hippocampus allows confirming these results in patients presenting with pre-dementia Alzheimer's Disease (AD), treated with donepezil in order to verify if this product is capable of stopping the speed of the atrophy of the hippocampus in patients and more specifically in those who will evolve to AD, compared to a placebo. This method is a semi automatic segmentation of the hippocampus from MRI, made by competitive region growing.
It was developed at the cognitive neurosciences and MRI laboratory in Pitié-Salpêtrière hospital. This method was validated on healthy subjects and Alzheimer's disease patients by comparison with manual segmentation.
Neuropsychological tests will be realized in order to supervise the clinical evolution of the patients and to correlate these results to the progression of the atrophy of the hippocampus.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||240 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders|
|Study Start Date :||November 2006|
|Primary Completion Date :||March 2008|
|Study Completion Date :||August 2010|
U.S. FDA Resources
|Experimental: Experimental 1||
Drug: Experimental 1
Drug: Donepezil Hydrochloride 10 mg orally for 12 months
|Placebo Comparator: Placebo Comparator||
Drug: Placebo Comparator
Drug: Placebo Matching placebo orally for 12 months
- Evolution of the volume of the Hippocampi, measured by magnetic resonance imaging (MRI), between D0 and final visit (12 months ). [ Time Frame: ( Day 0 to 12 months or in case of premature withdrawal after 6 months period ]
- Evolution of the neuropsychological scores between Day 0 and final visit. [ Time Frame: Day 0 to 12 during treatment and at 18 months follow up ]Outcome Measure Description: Patients will perform neuropsychological and independence tests including (16 items free recall/cued recall test using the Grober-Buschke method, Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR) sum of the boxes and Instrumental Activities of Daily Living (IADL), and will be evaluated using the Hamilton Scale.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00403520
|CHU Gui de Chauliac|
|Montpellier cedex, France|
|Study Director:||Isabelle Tonelli||Eisai France|